Axitinib - a small molecule inhibitor of vascular endothelial growth factor (VEGF), c-kit, and platelet derived growth factor receptor (PDGFR) - produced three partial responses (9 % ORR) in a single center trial for ACC [30]. This evidence concerns the gene KIT and adrenal cortex carcinoma.